We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GENERIC SERZONE MAY REMAIN ON THE MARKET, FDA SAYS
GENERIC SERZONE MAY REMAIN ON THE MARKET, FDA SAYS
July 7, 2004
The FDA has denied a citizen petition calling for the removal of Bristol-Myers Squibb’s (BMS’) antidepressant Serzone because of safety concerns — a move that allows generic firms to continue to market the drug, which no longer is sold by BMS.